Axel Rand1, Peter K Zahn2, Thomas A Schildhauer3, Christian Waydhas2,4, Uwe Hamsen2. 1. BG Universitätsklinikum Bergmannsheil, Klinik für Anästhesiologie, Intensiv-, Palliativ- und Schmerzmedizin, Bochum, Germany. axel.rand@gmail.com. 2. BG Universitätsklinikum Bergmannsheil, Klinik für Anästhesiologie, Intensiv-, Palliativ- und Schmerzmedizin, Bochum, Germany. 3. BG Universitätsklinikum Bergmannsheil, Klinik und Poliklinik für Chirurgie, Bochum, Germany. 4. Universität Duisburg-Essen, Medizinische Fakultät, Essen, Germany.
Abstract
BACKGROUND: Inhalative sedation is an emerging method for long-term sedation in intensive care therapy. There is evidence that it is easy to control and may be beneficial compared to intravenous sedation. Yet little is known about the use in patients with compromised lung function. In this retrospective analysis, we searched files of patients receiving inhalative sedation under venovenous extracorporeal membrane oxygenator (vv-ECMO) support due to lung failure. METHODS: After ethical approval, we performed a retrospective analysis of patients receiving vv-ECMO support and inhalative sedation in the surgical ICU in 2015. Isoflurane was administered via the AnaConDa®-system. Sedation was tested using Richmond Agitation and Sedation scale (RASS). RESULTS: 7 patients were identified. Median age was 50 years (26/70 years). All were male. Median ECMO runtime was 129 h (37/1008 h) and the survival rate was 57.9%. Dose of isoflurane was 1.7 ml/h (0.8 / 4.0 ml/h) resulting in expiratory concentrations of 0.8 Vol% (0.3/1.8 Vol%), inspiratory of 0.6 Vol% (0.1/1.4 Vol%). Higher concentrations of isoflurane were associated with increased depth of sedation (expiratory p = 0.016; inspiratory p = 0.027; averaged p = 0.015). With tidal volume below 350 ml, association was still present for expiratory and averaged concentrations of isoflurane (expiratory p = 0.031; inspiratory p = 0.082; average p = 0.039). CONCLUSIONS: This is the first study that shows that inhalative concentrations of isoflurane are associated with depth of sedation in patients with lung failure. We were able to show that even with major impacts in lung mechanics and function targeted sedation with volatile anaesthetics is feasible and dose-response relationship appears to exist.
BACKGROUND: Inhalative sedation is an emerging method for long-term sedation in intensive care therapy. There is evidence that it is easy to control and may be beneficial compared to intravenous sedation. Yet little is known about the use in patients with compromised lung function. In this retrospective analysis, we searched files of patients receiving inhalative sedation under venovenous extracorporeal membrane oxygenator (vv-ECMO) support due to lung failure. METHODS: After ethical approval, we performed a retrospective analysis of patients receiving vv-ECMO support and inhalative sedation in the surgical ICU in 2015. Isoflurane was administered via the AnaConDa®-system. Sedation was tested using Richmond Agitation and Sedation scale (RASS). RESULTS: 7 patients were identified. Median age was 50 years (26/70 years). All were male. Median ECMO runtime was 129 h (37/1008 h) and the survival rate was 57.9%. Dose of isoflurane was 1.7 ml/h (0.8 / 4.0 ml/h) resulting in expiratory concentrations of 0.8 Vol% (0.3/1.8 Vol%), inspiratory of 0.6 Vol% (0.1/1.4 Vol%). Higher concentrations of isoflurane were associated with increased depth of sedation (expiratory p = 0.016; inspiratory p = 0.027; averaged p = 0.015). With tidal volume below 350 ml, association was still present for expiratory and averaged concentrations of isoflurane (expiratory p = 0.031; inspiratory p = 0.082; average p = 0.039). CONCLUSIONS: This is the first study that shows that inhalative concentrations of isoflurane are associated with depth of sedation in patients with lung failure. We were able to show that even with major impacts in lung mechanics and function targeted sedation with volatile anaesthetics is feasible and dose-response relationship appears to exist.
Authors: L Gattinoni; A Pesenti; D Mascheroni; R Marcolin; R Fumagalli; F Rossi; G Iapichino; G Romagnoli; L Uziel; A Agostoni Journal: JAMA Date: 1986-08-15 Impact factor: 56.272
Authors: Christoph Wiesenack; Gunther Wiesner; Cornelius Keyl; Michael Gruber; Alois Philipp; Markus Ritzka; Christopher Prasser; Kai Taeger Journal: Anesthesiology Date: 2002-07 Impact factor: 7.892
Authors: Ralf Baron; Andreas Binder; Rolf Biniek; Stephan Braune; Hartmut Buerkle; Peter Dall; Sueha Demirakca; Rahel Eckardt; Verena Eggers; Ingolf Eichler; Ingo Fietze; Stephan Freys; Andreas Fründ; Lars Garten; Bernhard Gohrbandt; Irene Harth; Wolfgang Hartl; Hans-Jürgen Heppner; Johannes Horter; Ralf Huth; Uwe Janssens; Christine Jungk; Kristin Maria Kaeuper; Paul Kessler; Stefan Kleinschmidt; Matthias Kochanek; Matthias Kumpf; Andreas Meiser; Anika Mueller; Maritta Orth; Christian Putensen; Bernd Roth; Michael Schaefer; Rainhild Schaefers; Peter Schellongowski; Monika Schindler; Reinhard Schmitt; Jens Scholz; Stefan Schroeder; Gerhard Schwarzmann; Claudia Spies; Robert Stingele; Peter Tonner; Uwe Trieschmann; Michael Tryba; Frank Wappler; Christian Waydhas; Bjoern Weiss; Guido Weisshaar Journal: Ger Med Sci Date: 2015-11-12
Authors: Y Sawa; G Matsumiya; K Matsuda; E Tatsumi; T Abe; K Fukunaga; S Ichiba; T Taguchi; K Kokubo; T Masuzawa; A Myoui; M Nishimura; T Nishimura; T Nishinaka; E Okamoto; S Tokunaga; T Tomo; T Tsukiya; Y Yagi; T Yamaoka Journal: J Artif Organs Date: 2019-02-23 Impact factor: 1.731
Authors: Giacomo Grasselli; Marco Giani; Vittorio Scaravilli; Benedetta Fumagalli; Carminia Mariani; Sara Redaelli; Alberto Lucchini; Alberto Zanella; Nicolò Patroniti; Antonio Pesenti; Giuseppe Foti Journal: Crit Care Explor Date: 2021-01-08
Authors: Martin Bellgardt; Adrian Iustin Georgevici; Mitja Klutzny; Dominik Drees; Andreas Meiser; Philipp Gude; Heike Vogelsang; Thomas Peter Weber; Jennifer Herzog-Niescery Journal: Ann Intensive Care Date: 2019-10-16 Impact factor: 6.925